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Objectives: Buprenorphine/naloxone (BUP/NAL) combination is a well known 
treatment for opioid dependence. As a chronic relapsing disorder, some patients 
alternate between periods of on treatment and off treatment. The aim of this 
study was to compare health care resource utilization and costs between these 
patients and patients treated continuously. MethOds: Statistical analyses were 
conducted on a Medicaid insurance claims database (TruvenHealth MarketScan® 
Medicaid) from January 2007 to June 2012. Patients with at least two treatment 
episodes in the first year after the initial filled prescription were identified. The 
end of a treatment episode was defined as a period of 60 days with no filled BUP/
NAL prescriptions following the theoretical end of the last filled prescription. An 
ordered logistic regression model was used to analyze the impact of initial treat-
ment episode duration on the number of new episodes in the year following the 
end of the first episode. Health care resource utilization and related costs during 
the first year after initiation were compared between the two groups. Results: 
2,223 patients were included in the analysis. During the first year, 86% of patients 
had only one treatment episode, 13% had two and 1% had three. Compared to 
patients who remained in treatment continuously over 12 months, the multiple 
treatment episode group had lower medication costs (-$2,877) but higher psychi-
atric inpatient costs (+$720), non-psychiatric inpatient costs (+$2001) and emer-
gency room costs (+430) over 12 months. Total health care costs over 12 months 
were higher among multiple treatment episode patients ($16,583 vs. $15.123, 
p= 0.0004). cOnclusiOns: Despite lower medication costs, total health care costs 
over 12 months were higher among patients with multiple treatment episodes 
compared to patients treated continuously.
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Objectives: To compare the treatment cost of paliperidone palmitate (PP) versus 
risperidone long acting (R-LA), both indicated for the treatment of schizophrenia in 
Brazil. MethOds: In Brazil, both (PP and R-LA) long acting 2nd generation antipsy-
chotics are approved for the treatment of schizophrenia. Published literature shows 
no difference in safety and efficacy between them; therefore, a cost-minimization 
analysis was performed. Yearly treatment costs were calculated for an average dose 
of 37,5 mg per patient in the case of R-LA and 75 mg in the case of PP. The two initial 
treatment doses were considered: for PP, 150 mg on the 1st day and 100 mg on the 
8th day, and for R-LA 21 days oral supplementation with 3 mg of risperidone, accord-
ing to dosing intervals defined in the product label. Prices were gathered from the 
official price list (CMED – Apr’14). Results: PP has the lowest cost of treatment, 
at R$ 12,739 per patient in the 1st year – against R-LA R$ 18,165 – and R$ 11,359 in 
the 2nd year (R-LA has R$ 17,971). Treatment with PP compared to R-LA may bring 
important savings to the payers (HMOs or Government), with potential to reduce 
the cost of treatment by 30% in the 1st year, and 37% in the 2nd year - allowing a 
higher number of patients to be treated at the same budget level. cOnclusiOns: 
Although both molecules, PP and R-LA, have demonstrated similar efficacy, PP offers 
a cost reduction from the perspective of the Brazilian private health care system 
compared to R-LA. In addition, PP offers advantages that can have additional value 
for public and private payers alike such as a monthly injection and no need for 
cold chain. PP can therefore be considered a cost-saving therapeutic option for 
schizophrenia compared to R-LA.
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Approximately 10-20% of individuals with Major Depressive Disorder (MDD) fail to 
respond to antidepressant monotherapy. These individuals with treatment resist-
ant depression (TRD) have been found to be frequent users of health care services, 
thus incurring significantly greater costs than those without TRD. Objectives: 
To investigate the cost of Treatment-Resistant Depression from a private payer 
perspective in Canada. MethOds: An employer-sponsored benefits plan data-
base (2011/2012) was used to define a cohort of Non-TRD and TRD claimants. TRD 
claimants are defined as those on their third antidepressant monotherapy; or 
combination antidepressant therapy; or antidepressant augmented with lithium, 
thyroid hormone or an antipsychotic medication. The cost of prescription medica-
tion utilization, short-term disability (STD), and long-term disability (LTD) benefits 
for employees was calculated (2011 and 2012 $CAN) for both Non-TRD and TRD 
groups. Descriptive statistics were used to characterize the cohort of claimants 
and employees, as well as resources and costs for employees. Results: There 
were 55,324 and 61,028 employee claimants in 2011 and 2012, respectively. 717 
(1.3%) and 798 (1.3%) were TRD claimants; 4,744 (8.6%) and 5,137 (8.4%) were Non-
TRD claimants in 2011 and 2012, respectively. In 2011, the medication costs for 
treating depression was $774 per TRD employee claimant compared to $303 per 
Non-TRD claimant. STD costs were $6,263 for TRD (n= 79) and $5,855 for Non-TRD 
(n= 276). LTD costs were $13,598 for TRD (n= 80) and $12,272 for Non-TRD (n= 119). 
In 2012, the medication costs for treating depression per TRD employee claimant 
was $794 compared to $293 for Non-TRD claimants. STD costs were $7,832 for TRD 
(n= 86) and $4,001 for Non-TRD (n= 248). LTD costs were $13,927 for TRD (n= 89) 
and $12,901 for Non-TRD (n= 121). cOnclusiOns: Claimants identified with TRD 
had higher medication, STD and LTD costs than those with Non-TRD. Limitations 
include lack of diagnostic information for claimants and small sample sizes for 
STD and LTD subgroups.
Objectives: Major depressive disorder affects approximately 10-15% of the popu-
lation and is associated with significant morbidity and mortality. It is one of the 
leading causes of disability in young adults. A large proportion of the burden can be 
attributed to treatment-resistant depression (TRD). To understand the prevalence 
and disease burden of TRD in Western European countries, the US and Canada, a 
systematic literature search was performed. MethOds: OVID, the Cochrane Library 
and the CRD database were used to retrieve TRD publications in English language 
from January 2003-October 2013. In total, 6306 abstracts were identified. Predefined 
selection criteria regarding study design, patient population (age ≥ 12 years; US, 
Canada, Germany, Italy, France, Spain or UK; TRD defined as one treatment failure 
and high symptom severity e. g. MADRS ≥ 31, or an inadequate response to ≥ two 
antidepressants) and outcomes of interest were applied. Results: Only seven stud-
ies included prevalence and/or disease burden data. Five studies provided preva-
lence estimates which adhered to the strict TRD definition used for this review. 
Study design and definition of the patient population were critical in determining 
the prevalence rates, with the lowest rates found in US employer claims databases 
(11-15%), higher rates in commercial health insurance databases (29-31%) and the 
highest rates in a European multicenter study (51-56%). The database studies mainly 
included employed patients thereby likely underestimating the prevalence, whereas 
the European study likely overestimated the prevalence due to a less stringent TRD 
definition. Inconsistent data were reported regarding treatment outcomes, comor-
bidities, hospitalization and work productivity. There was no information on other 
outcomes such as health-related quality of life or functioning. cOnclusiOns: No 
consistent data were found in the literature from January 2003-October 2013 regard-
ing the epidemiology and disease burden of TRD. To determine the prevalence and 
disease burden for TRD, further studies are needed.
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Objectives: The aim of this study was to estimate the prevalence of metabolic syn-
drome (MS) in patients with schizophrenia according to the presence or absence of 
negative symptoms. MethOds: A retrospective, cohort study was conducted using 
electronic medical records from the health provider BSA (Badalona, Spain). All adult 
outpatients with a diagnosis of schizophrenia were followed for 12 months. Two study 
groups were defined by the presence or absence of negative symptoms based on the 
PANSS Marder Negative Symptoms Factor (N1-N4, N6, G7 and G16). MS prevalence was 
estimated using the NCEP ATP III criteria. Descriptive statistics and logistic regres-
sion models were applied. Results: We studied 1,120 patients (mean age: 46.8 ± 
13.8 years; male: 58.4%). One or more negative symptoms were present in 52.5% of 
patients (95%CI: 49.6-55.4%). Dyslipidemia (48.7%), hypertension (38.2%), and diabetes 
mellitus (19.3%) were the most frequent comorbid conditions. Quetiapine, risperidone 
and olanzapine were the most common antipsychotic drugs administered. Patients 
with negative symptoms showed a greater mean number of comorbid conditions than 
patients without this symptomatology (8.5 and 7.0, respectively; p< 0.001). Prevalence 
of MS was 38.6% (CI: 35.7-41.5%), higher among patients with one or more negative 
symptoms (43.9% vs. 34.9%, respectively; p= 0.002). MS was associated with the pres-
ence of negative symptoms, age, and comorbidity (OR= 1.6, 1.2, and 1.2, respectively; 
p< 0.05). cOnclusiOns: Further studies are necessary to elucidate the association 
between the presence of negative symptoms and MS among patients with schizo-
phrenia as well as the underlying mechanisms involved.
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Objectives: To quantify the economic burden of schizophrenia relapse in 
Brazil, and to estimate the impact of atypical Long Acting Injectables (LAIs) on 
relapse. MethOds: Administrative health service data from a Brazilian public system 
database (DATASUS) were used to estimate the number of relapse patients and related 
resource utilisation. Corresponding data for private system patients were estimated 
based on published literature and by extrapolating DATASUS data. A prevalence-based 
costing with a mixed bottom-up and top-down approach was used to quantify direct 
and indirect costs, disability adjusted life years (DALYS) and their associated monetary 
value. A decision-analytic model was constructed to evaluate the cost effectiveness 
of potentially transferring non-compliant patients from oral antipsychotics to atypi-
cal LAIs. All costs are presented in 2013 Brazilian real. Results: In 2011-12, 88,721 
patients with schizophrenia in Brazil experienced 263,037 episodes of relapse that 
resulted in hospital or outpatient care. The potential avoidable health care cost of 
relapse was R$722.6 million. The estimated additional health care cost per DALY 
avoided was R$5,049 if non-compliant patients could be transferred to atypical LAIs 
to achieve 5% overall utilisation. Reducing relapses would give Brazil potential avoid-
ance of 1,335 DALYs, which corresponds to a saving of R$482.8 million in the stock 
of health capital. cOnclusiOns: The economic burden of schizophrenia relapse in 
Brazil is significant. Brazilian policymakers should provide greater access to LAIs.
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